<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097577</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20100004H</org_study_id>
    <nct_id>NCT01097577</nct_id>
  </id_info>
  <brief_title>A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery</brief_title>
  <official_title>A Comparison of Pregabalin (Lyrica®) to Placebo in Postoperative Pain Relief of Patients Status-post Photorefractive Keratectomy: A Double-masked Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>59th Medical Wing</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>59th Medical Wing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of pregabalin to placebo for&#xD;
      postoperative pain control after photorefractive keratectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study subjects will be taken from a standard group of typical candidates for PRK surgery&#xD;
      including active duty and DoD (Department of Defense) beneficiaries. Prior to being&#xD;
      approached for the study, all patients will have had a previous desire for surgery and had a&#xD;
      pre-operative evaluation indicating healthy ocular status.&#xD;
&#xD;
      Patients scheduled for PRK surgery will be briefed on the purpose of the study and invited to&#xD;
      participate at the preoperative appointment. After the consent process, patients will be&#xD;
      randomized in a 1:1 fashion to receive either oral pregabalin 75mg twice daily or placebo for&#xD;
      pain control, in addition to the standard care treatment of as needed Percocet and tetracaine&#xD;
      ophthalmic drops. Subjects will be evaluated daily for 4 days post-operatively for subjective&#xD;
      pain assessment, adverse drug events and compliance, use of concomitant medications as well&#xD;
      as monitoring of healing time. Quality of life will be measured at baseline and post-op day 2&#xD;
      when the peak of pain is anticipated. Analysis will be performed to detect an approximate 10%&#xD;
      improvement in pain scores. Secondary outcomes will include measuring healing time, quality&#xD;
      of life and use of rescue medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Efficacy</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Primary efficacy is assessed on 100mm Visual Analog Scale (VAS); total range is 0 to 100. A score closer to zero indicates a better outcome of less pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PPI Score</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Secondary efficacy is assessed with present pain intensity (PPI) score. Scale is 0 (no pain) to 5 (excruciating pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total MPQ Score</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Secondary efficacy is assessed using the Total MPQ Score. Scale minimum is 0 (no pain) to maximum of 45 (severe pain). A higher score indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - BPI</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if there was an improvement in the patient's functional health and well-being associated with pregabalin compared to standard of care as assessed by Brief Pain Inventory-short form (BPI-SF). Data was assessed on the day of surgery (Day 0) and at the expected peak of pain, postop Day 2 in the morning. Scale is minimum 0 (no pain) to maximum of 10 (pain as bad as you can imagine). A higher score indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy 2</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if there was a reduction in the need for use of rescue pain medications, Percocet and tetracaine, in those subjects who received pregabalin. Total number of doses was collected. A higher number of doses required indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelial Healing Time</measure>
    <time_frame>5 days or more</time_frame>
    <description>Determine if there was a reduction in healing time associated with pregabalin as seen with daily slit-lamp observation. Epithelial defect was measured at post-operative day 3, 5, 7, and 9 in each eye. A higher number of days required for healing indicates a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Pregabalin 75 mg capsule twice daily administered prior to PRK and continued for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo capsule (Lactose) twice daily administered prior to PRK and continued for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.</description>
    <arm_group_label>pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy ocular status&#xD;
&#xD;
          -  Stable preoperative refractive anisometropia&#xD;
&#xD;
          -  Consented to the PRK surgical procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Diagnosed with autoimmune disease or diabetes&#xD;
&#xD;
          -  Patients with a known adverse reaction or hypersensitivity to gabapentin or pregabalin&#xD;
&#xD;
          -  Patients only desiring PRK on one eye&#xD;
&#xD;
          -  Patients with history of drug use/abuse/addiction&#xD;
&#xD;
          -  Patients who are on chronic pain medications&#xD;
&#xD;
          -  Patients currently taking anti-epileptic, antidepressant and/or anti-psychotic&#xD;
             medications&#xD;
&#xD;
          -  Patients with a history of suicidality&#xD;
&#xD;
          -  Patients with chronic renal insufficiency (defined as estimated creatinine clearance&#xD;
             less than 30ml/min or Scr ≥ 2.0) 10) Patients who have experienced angioedema, or have&#xD;
             heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M Meek, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>59th Medical Wing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Reilly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>59th Medical Wing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Bonnie Rosbolt, PharmD, CCRC</last_name>
    <role>Study Director</role>
    <affiliation>59th Medical Wing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilford Hall Medical Center - Refractive Surgery Center</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <zip>78236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Meek JM, Rosbolt MB, Taylor KR, Fusco EA, Panday VA, Reilly CD. Pregabalin versus placebo in postoperative pain relief of patients' status post photorefractive keratectomy: a double-masked, randomized, prospective study. J Ocul Pharmacol Ther. 2014 Sep;30(7):527-32. doi: 10.1089/jop.2013.0208. Epub 2014 Jun 10.</citation>
    <PMID>24914779</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>October 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2020</results_first_posted>
  <last_update_submitted>October 3, 2020</last_update_submitted>
  <last_update_submitted_qc>October 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>59th Medical Wing</investigator_affiliation>
    <investigator_full_name>Julie Meek</investigator_full_name>
    <investigator_title>Clinical Pharmacist</investigator_title>
  </responsible_party>
  <keyword>photorefractive keratectomy</keyword>
  <keyword>excimer laser</keyword>
  <keyword>PRK</keyword>
  <keyword>pain, postoperative</keyword>
  <keyword>pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin</title>
          <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
        </group>
        <group group_id="P2">
          <title>Lactose Capsule</title>
          <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin</title>
          <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
        </group>
        <group group_id="B2">
          <title>Lactose Capsule</title>
          <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" lower_limit="21" upper_limit="57"/>
                    <measurement group_id="B2" value="35.1" lower_limit="21" upper_limit="57"/>
                    <measurement group_id="B3" value="34.85" lower_limit="21" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Efficacy</title>
        <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Primary efficacy is assessed on 100mm Visual Analog Scale (VAS); total range is 0 to 100. A score closer to zero indicates a better outcome of less pain.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Lactose Capsule</title>
            <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Efficacy</title>
          <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Primary efficacy is assessed on 100mm Visual Analog Scale (VAS); total range is 0 to 100. A score closer to zero indicates a better outcome of less pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="2.51"/>
                    <measurement group_id="O2" value="1.33" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.56" spread="10.95"/>
                    <measurement group_id="O2" value="10.34" spread="16.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 1 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.32" spread="9.14"/>
                    <measurement group_id="O2" value="10.22" spread="15.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 1 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.32" spread="21.95"/>
                    <measurement group_id="O2" value="27.09" spread="25.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 2 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.49" spread="21.31"/>
                    <measurement group_id="O2" value="29.27" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 2 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.14" spread="22.79"/>
                    <measurement group_id="O2" value="25.78" spread="26.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 3 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.48" spread="12.84"/>
                    <measurement group_id="O2" value="8.76" spread="15.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 3 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="6.74"/>
                    <measurement group_id="O2" value="6.02" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 4 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="4.56"/>
                    <measurement group_id="O2" value="2.65" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study was designed to determine if pregabalin is an effective regimen for postoperative pain control following PRK. We hypothesized that there will be at least a 10% improvement in pain after PRK using a scheduled pregabalin dosing regimen compared to placebo. A power analysis was completed to determine the number of patients necessary.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.180</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PPI Score</title>
        <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Secondary efficacy is assessed with present pain intensity (PPI) score. Scale is 0 (no pain) to 5 (excruciating pain)</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Lactose Capsule</title>
            <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>PPI Score</title>
          <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Secondary efficacy is assessed with present pain intensity (PPI) score. Scale is 0 (no pain) to 5 (excruciating pain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.17"/>
                    <measurement group_id="O2" value="0.03" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.76"/>
                    <measurement group_id="O2" value="0.84" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 1 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.73"/>
                    <measurement group_id="O2" value="0.89" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 1 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.89"/>
                    <measurement group_id="O2" value="1.62" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 2 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.89"/>
                    <measurement group_id="O2" value="1.62" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 2 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.94"/>
                    <measurement group_id="O2" value="1.48" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 3 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.77"/>
                    <measurement group_id="O2" value="0.68" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 3 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.58"/>
                    <measurement group_id="O2" value="0.48" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 4 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.46"/>
                    <measurement group_id="O2" value="0.22" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.207</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total MPQ Score</title>
        <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Secondary efficacy is assessed using the Total MPQ Score. Scale minimum is 0 (no pain) to maximum of 45 (severe pain). A higher score indicates a worse outcome.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Lactose Capsule</title>
            <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Total MPQ Score</title>
          <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ). Secondary efficacy is assessed using the Total MPQ Score. Scale minimum is 0 (no pain) to maximum of 45 (severe pain). A higher score indicates a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.47"/>
                    <measurement group_id="O2" value="0.16" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="2.28"/>
                    <measurement group_id="O2" value="2.18" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 1 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="2.16"/>
                    <measurement group_id="O2" value="2.16" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 1 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="5.07"/>
                    <measurement group_id="O2" value="5.37" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 2 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="3.9"/>
                    <measurement group_id="O2" value="5.61" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 2 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="4.1"/>
                    <measurement group_id="O2" value="5.68" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 3 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.34"/>
                    <measurement group_id="O2" value="2.9" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 3 evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="2.02"/>
                    <measurement group_id="O2" value="1.16" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop day 4 morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.35"/>
                    <measurement group_id="O2" value="0.39" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.283</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - BPI</title>
        <description>Determine if there was an improvement in the patient's functional health and well-being associated with pregabalin compared to standard of care as assessed by Brief Pain Inventory-short form (BPI-SF). Data was assessed on the day of surgery (Day 0) and at the expected peak of pain, postop Day 2 in the morning. Scale is minimum 0 (no pain) to maximum of 10 (pain as bad as you can imagine). A higher score indicates a worse outcome.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Lactose Capsule</title>
            <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - BPI</title>
          <description>Determine if there was an improvement in the patient's functional health and well-being associated with pregabalin compared to standard of care as assessed by Brief Pain Inventory-short form (BPI-SF). Data was assessed on the day of surgery (Day 0) and at the expected peak of pain, postop Day 2 in the morning. Scale is minimum 0 (no pain) to maximum of 10 (pain as bad as you can imagine). A higher score indicates a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at its Worst, Day0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="1.02"/>
                    <measurement group_id="O2" value="0.24" spread="1.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at its Worst, Day2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="2.511"/>
                    <measurement group_id="O2" value="4.67" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at its Least, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.519"/>
                    <measurement group_id="O2" value="0.08" spread="0.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at its least, Day2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="1.588"/>
                    <measurement group_id="O2" value="1.48" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg Pain, Day0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.693"/>
                    <measurement group_id="O2" value="0.33" spread="1.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Avg Pain, Day2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="1.929"/>
                    <measurement group_id="O2" value="3.03" spread="2.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference, Day0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.484"/>
                    <measurement group_id="O2" value="0.13" spread="0.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference, Day2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="2.161"/>
                    <measurement group_id="O2" value="3.5" spread="2.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Question 1: Pain at its worst</non_inferiority_desc>
            <p_value>0.223</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Efficacy 2</title>
        <description>Determine if there was a reduction in the need for use of rescue pain medications, Percocet and tetracaine, in those subjects who received pregabalin. Total number of doses was collected. A higher number of doses required indicates a worse outcome.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Lactose Capsule</title>
            <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Efficacy 2</title>
          <description>Determine if there was a reduction in the need for use of rescue pain medications, Percocet and tetracaine, in those subjects who received pregabalin. Total number of doses was collected. A higher number of doses required indicates a worse outcome.</description>
          <units>Rescue medication doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surgery Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.234"/>
                    <measurement group_id="O2" value="0.94" spread="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.842"/>
                    <measurement group_id="O2" value="2.44" spread="2.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.633"/>
                    <measurement group_id="O2" value="2.56" spread="2.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.802"/>
                    <measurement group_id="O2" value="0.62" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epithelial Healing Time</title>
        <description>Determine if there was a reduction in healing time associated with pregabalin as seen with daily slit-lamp observation. Epithelial defect was measured at post-operative day 3, 5, 7, and 9 in each eye. A higher number of days required for healing indicates a worse outcome.</description>
        <time_frame>5 days or more</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Lactose Capsule</title>
            <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Epithelial Healing Time</title>
          <description>Determine if there was a reduction in healing time associated with pregabalin as seen with daily slit-lamp observation. Epithelial defect was measured at post-operative day 3, 5, 7, and 9 in each eye. A higher number of days required for healing indicates a worse outcome.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days to Heal OD (Right Eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1.087"/>
                    <measurement group_id="O2" value="2.9" spread="0.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days to Heal OS (Left Eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="1.164"/>
                    <measurement group_id="O2" value="2.9" spread="0.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Days to Heal, OD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.581</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Days to Heal, OS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.307</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <desc>Adverse events were self-reported by the patients to the investigators at each follow-up evaluation.&#xD;
Each adverse event reported was monitored daily until resolution.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin</title>
          <description>pregabalin: 1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
        </group>
        <group group_id="E2">
          <title>Lactose Capsule</title>
          <description>Placebo: 1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea/congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie Meek, Clinical Pharmacist</name_or_title>
      <organization>US Air Force</organization>
      <phone>210-808-2200</phone>
      <email>julie.m.meek.mil@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

